A Phase 1 study of the blood-stage malaria vaccine candidate AMA1-C1/Alhydrogel® with CPG 7909, using two different formulations and dosing intervals

Ítems similars

• Phase 1 Trial of AMA1-C1/Alhydrogel plus CPG 7909: An Asexual Blood-Stage Vaccine for Plasmodium falciparum Malaria
  per: Mullen, Gregory E. D., et al.
  Publicat: (2008)
• Phase 1 Trial of the Plasmodium falciparum Blood Stage Vaccine MSP1(42)-C1/Alhydrogel with and without CPG 7909 in Malaria Naïve Adults
  per: Ellis, Ruth D., et al.
  Publicat: (2010)
• A Randomized, Controlled, Phase 1 Study of the Safety and Immunogenicity of the AMA1-C1/Alhydrogel(®) + CPG 7909 Vaccine for Plasmodium falciparum Malaria, in Semi-immune Malian Adults
  per: Sagara, Issaka, et al.
  Publicat: (2009)
• Impact on Malaria Parasite Multiplication Rates in Infected Volunteers of the Protein-in-Adjuvant Vaccine AMA1-C1/Alhydrogel+CPG 7909
  per: Duncan, Christopher J. A., et al.
  Publicat: (2011)
• Phase 1 study in malaria naïve adults of BSAM2/Alhydrogel®+CPG 7909, a blood stage vaccine against P. falciparum malaria.
  per: Ruth D Ellis, et al.
  Publicat: (2012-01-01)